Alnylam collaboration with Genzyme a 'major positive,' says Leerink Leerink views Alnylam's (ALNY) expanded collaboration with Sanofi's (SNY) Genzyme as a major positive and thinks the stock could be sharply higher today. Further, the firm thinks Sirna could be worth more than the $175M deal price to Alnylam. Leerink keeps an Outperform rating on the stock.
Alnylam weakness a buying opportunity, says Deutsche Bank Deutsche Bank said Alnylam's Phase 1 AT-3 conference presentation update was positive, as expected, supporting safety and efficacy. The firm's analyst said weakness could be due to fast money selling and recommends buying shares on weakness.